# US 2026/0061173 A1 · Arginine modified chitosan/polyvinyl alcohol hydrogel microneedle transdermal delivery patches for wound healing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061173 A1
- Document ID: US20260061173A1
- Status: Published application
- Kind: A1
- Application number: 18/818,588
- Filed: 2024-08-29
- Published: 2026-03-05
- Earliest claimed: 2024-08-29
- Inventors: Muhammad Raza Shah; Muhammad Hasnain; Maria Khalid
- Web page: https://patentgrep.com/patent/US20260061173A1

## CPC

- A61M 37/0015: {by using microneedles}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 31/12: Ketones
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M 2037/0046: {Solid microneedles}
- A61M 2037/0061: {Methods for using microneedles}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a microneedle-based transdermal delivery patch fabricated from a hydrogel composed of polyvinyl alcohol (PVA), arginine-modified chitosan, and a crosslinker. The arginine-modified chitosan is prepared by reacting a chitosan solution with an arginine solution preactivated with N-hydroxy succinimide and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide at a specific pH. The hydrogel's formulation further comprises a PVA concentration ranging from 10% to 12% (w/v). arginine-modified chitosan and PVA solution are mixed in a 1:2 ratio by volume and are crosslinked using trimethyl orthoformate (TMOF). The patch is further loaded with curcumin, with a concentration of 120μg per patch, demonstrating a 70% release over 48 hours in a controlled manner. This invention represents the first application of PVA crosslinked arginine-modified chitosan hydrogel loaded with curcumin specifically for animal wound healing, providing enhanced wound healing and antibacterial efficacy.

## Claims

### Claim at position 1

1: A hydrogel microneedle-based transdermal delivery patch, wherein the patch is fabricated using a hydrogel composition that comprises polyvinyl alcohol (PVA), arginine-modified chitosan, and a crosslinker, and can deliver one or more therapeutic agents transdermally.

### Claim at position 2 (depends on 1)

2: The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the arginine-modified chitosan is prepared by modifying 5 mL of a 0.3% (w/v) chitosan solution at pH 5.5 with 3 mL of a 0.04 mM arginine solution, preactivated with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.

### Claim at position 3 (depends on 1)

3: The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the concentration of PVA ranges from 10% to 12% (w/v).

### Claim at position 4 (depends on 1)

4: The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the arginine-modified chitosan and PVA solutions are mixed in a 1:2 ratio by volume.

### Claim at position 5 (depends on 1)

5: The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the concentration of the crosslinker, trimethyl orthoformate (TMOF), is 4% (v/v) relative to the total volume of the polymeric mixture.

### Claim at position 6 (depends on 1)

6: The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the patch comprises a 15×15 array of pyramidal microneedles, with each microneedle having an average height of 340±5 μm and an average base length of 244±3 μm.

### Claim at position 7 (depends on 1)

7: The hydrogel microneedle-based transdermal delivery patch of claim 1, wherein the patch is designed for the transdermal delivery of curcumin as a therapeutic agent, and further incorporates 1 mL of 2 mg/mL methanolic curcumin.

### Claim at position 8 (depends on 7)

8: The hydrogel microneedle-based transdermal delivery patch of claim 7, wherein the curcumin amount is 120 μg per patch.

### Claim at position 9 (depends on 7)

9: The hydrogel microneedle-based transdermal delivery patch of claim 7, wherein the patch demonstrates a 70% release of the loaded curcumin over a 48-hour period in a controlled-release manner.

### Claim at position 10 (depends on 7)

10: The hydrogel microneedle-based transdermal delivery patch of claim 7, wherein the patch demonstrates healing of animal wounds.